(Reuters) -London-based startup SheMed, which offers personalized weight-loss plans using popular medicines Wegovy and Mounjaro, said on Thursday it has raised $50 million in its Series A funding round to expand its operations across the United Kingdom.

Demand for Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro has surged across Britain, with patients often facing longer wait times to access the treatments through the National Health Service.

Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has added over 60,000 members in less than a year.

“The demand for SheMed’s services has been extraordinary,” said Olivia Ferro, who holds the CEO position at the company.

Women make up a majority of patients that use GLP-1 drugs, the class of treatments to which Mounjaro and Wegovy be

See Full Page